Objectif ULTRA-DD (Unrestricted Leveraging of Targets for Research Advancement and Drug Discovery) will be an European-wide, highly collaborative and inclusive consortium, to validate new targets for drug discovery by (1) generating high quality research tools, with an emphasis on chemical probes; (2) generating the chemical probes in the most cost-effective manner, using structure-guided methods and harnessing the chemical libraries and medicinal chemistry skills of the EFPIA participants; (3) testing the chemical probes in models of human disease based on continuous access to cells from patients with selected inflammatory diseases; and (4) making all reagents and knowledge available to the research community without restriction on use, to expand the impact well beyond the ULTRA-DD partners. In addition to our focus on chemical probes, we will also generate a defined set of antibodies targeting extracellular and membrane bound proteins of relevance to disease. To accomplish the above, ULTRA-DD will create two scientific Cores and formalize a collaborative network of SMEs, academic scientists and clinicians. The Protein Characterization and Tool-Generation Core will comprise four integrated laboratories: University of Oxford’s Structural Genomics Consortium laboratory, led by Chas Bountra (OXF-SGC), ETH in Zurich (ETHZ), led by Ruedi Aebersold, Karolinska Institutet (KI-MBB), led by Susanne Gräslund, and the University of Toronto’s SGC laboratory (UTOR-SGC, will not receive IMI funds), led by Cheryl Arrowsmith, and chemical biology teams in Bayer (Bayer), Janssen (JPNV), Novartis (NOV) and Pfizer (Pfizer). The Clinical Immunology Core will generate high quality assays from patient-derived cells and tissues in selected inflammatory diseases, and test effects of the chemical and antibody probes. This Core comprises the Kennedy Institute (UOXF-KENN) in the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences at the University of Oxford (UOXF-NDORMS), led by Marc Feldmann, the Centre for Molecular Medicine (KI-CMM) at Karolinska Institutet, led by Lars Klareskog and Per-Johan Jakobsson, and DiscoveRx (DRX, Sanj Kumar), an SME based in Birmingham, UK (will not receive IMI funds). The activities within the Cores will be enhanced significantly and the impact of the output expanded dramatically through the involvement of a Collaborative Network of SMEs, IMI projects, academic scientists and Disease Foundations (Appendices 1-3; none of these networks will receive IMI funds). The network will include a Target Prioritization Network (TPN) of top genomicists and clinicians; a Science and Technology Network (STN) that contributes expertise across the ULTRA-DD “gene to chemical probe” pipeline; and an Inflammatory Disease Network (IDN) of clinicians and translational scientists that provides enhanced access to disease-relevant expertise and patient tissue, as well as an expanded array of innovative assays. Each member of the ULTRA-DD network will commit to the open access policy. ULTRA-DD will be managed by the SGC (London, UK), which is a charitable company that has an enviable track record in managing the scientific, legal and financial aspects of open access public-private partnerships. The vision of ULTRA-DD is to create an open access consortium that provides industry with a stream of high quality target-disease associations and tools to study them. Our aspiration is to provide the evidence that convinces industry to launch >10 novel proprietary drug discovery programs based on ULTRA-DD open access output during the course of the project and in the nearest years following completion (2020).ULTRA-DD will meet the deliverables by integrating teams of tool-generating scientists with expert clinicians with access to patient tissue, under an open access, milestone-driven framework, and will expand its output through organized collaborations with innovative European scientists, leading non-European scientists Champ scientifique medical and health sciencesbasic medicinepharmacology and pharmacydrug discoverymedical and health sciencesclinical medicinerheumatologymedical and health scienceshealth sciencesinflammatory diseasesmedical and health sciencesbasic medicinemedicinal chemistrymedical and health sciencesclinical medicineorthopaedics Programme(s) FP7-JTI - Specific Programme "Cooperation": Joint Technology Initiatives Thème(s) IMI-JU-11-2013-05 - Generation Of Research Tools To Enable The Translation Of Genomic Discoveries Into Drug Discovery Projects Appel à propositions IMI-JU-11-2013 Voir d’autres projets de cet appel Régime de financement JTI-CP-IMI - Joint Technology Initiatives - Collaborative Project (IMI) Coordinateur NOVARTIS PHARMA AG Contribution de l’UE Aucune donnée Adresse LICHTSTRASSE 35 4056 Basel Suisse Voir sur la carte Région Schweiz/Suisse/Svizzera Nordwestschweiz Basel-Stadt Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Chercheur principal Nils Ostermann (Dr) Contact administratif Stephan Korte (Dr) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée Participants (9) Trier par ordre alphabétique Trier par contribution de l’UE Tout développer Tout réduire STRUCTURAL GENOMICS CONSORTIUM LBG Royaume-Uni Contribution de l’UE € 1 353 696,00 Adresse EUSTON ROAD 215 NW1 2BE London Voir sur la carte Région London Inner London — West Camden and City of London Type d’activité Research Organisations Contact administratif Paul Van Damme (Mr.) Liens Contacter l’organisation Opens in new window Coût total Aucune donnée BAYER AKTIENGESELLSCHAFT Allemagne Contribution de l’UE Aucune donnée Adresse KAISER-WILHELM-ALLEE 1 51373 Leverkusen Voir sur la carte Région Nordrhein-Westfalen Köln Leverkusen, Kreisfreie Stadt Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Contact administratif Petra Freitag (Mrs) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée DiscoveRx Corp Ltd Royaume-Uni Contribution de l’UE Aucune donnée Adresse Faraday Wharf, Innovation Birmingham Campus, Holt Street, Birmingham Science Park Aston B7 4BB Birmingham Voir sur la carte Contact administratif Richard Price (Mr) Liens Contacter l’organisation Opens in new window Coût total Aucune donnée EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH Suisse Contribution de l’UE € 1 440 970,00 Adresse Raemistrasse 101 8092 Zuerich Voir sur la carte Région Schweiz/Suisse/Svizzera Zürich Zürich Type d’activité Higher or Secondary Education Establishments Contact administratif Martin Pestalozzi (Mr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée JANSSEN PHARMACEUTICA NV Belgique Contribution de l’UE Aucune donnée Adresse TURNHOUTSEWEG 30 2340 Beerse Voir sur la carte Région Vlaams Gewest Prov. Antwerpen Arr. Turnhout Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Contact administratif Henk Sipma (Mr) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée KAROLINSKA INSTITUTET Suède Contribution de l’UE € 4 902 660,00 Adresse Nobels Vag 5 17177 Stockholm Voir sur la carte Région Östra Sverige Stockholm Stockholms län Type d’activité Higher or Secondary Education Establishments Contact administratif Caroline HAMILTON (Ms.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD Royaume-Uni Contribution de l’UE € 13 502 674,00 Adresse WELLINGTON SQUARE UNIVERSITY OFFICES OX1 2JD Oxford Voir sur la carte Région South East (England) Berkshire, Buckinghamshire and Oxfordshire Oxfordshire Type d’activité Higher or Secondary Education Establishments Contact administratif Gill Wells (Ms) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée PFIZER LIMITED Royaume-Uni Contribution de l’UE Aucune donnée Adresse RAMSGATE ROAD CT13 9NJ Sandwich Voir sur la carte Région South East (England) Kent East Kent Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Contact administratif Carla Cox (Dr) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO Canada Contribution de l’UE Aucune donnée Adresse KINGS COLLEGE CIRCLE 27 M5S 1A1 Toronto Voir sur la carte Type d’activité Higher or Secondary Education Establishments Contact administratif Arij Al Chawaf (Dr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée